Gebrauch von non-steroidal antiinflammatory drugs in der Therapie primärer Kopfschmerzerkrankungen

O. Summ; S. Evers

doi:10.1055/s-0038-1628488

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2013; 32(03): 126-131
DOI: 10.1055/s-0038-1628488

Kopfschmerzen

Schattauer GmbH

Gebrauch von non-steroidal antiinflammatory drugs in der Therapie primärer Kopfschmerzerkrankungen

Use of non-steroidal antiinflammatory drugs in the therapy of primary headaches

O. Summ

¹Klinik für Neurologie, Universitätsklinikum Münster

,

S. Evers

¹Klinik für Neurologie, Universitätsklinikum Münster

²Krankenhaus Lindenbrunn, Coppenbrügge

› Institutsangaben

Abstract

Zusammenfassung

Seit Jahrzehnten werden non-steroidal antiinflammatory drugs (NSAID) mit großem Erfolg in der Behandlung primärer Kopfschmerzerkrankungen eingesetzt und haben einen festen Platz in der Behandlung der Migräne als auch des Kopfschmerzes vom Spannungstyp. Für die weiteren primären Kopfschmerzerkrankungen bestehen Empfehlungen, welche weiter zu einem differenzierten Gebrauch ermutigen. Trotz des Wissens über die Interaktion der NSAID mit Cyclooxygenase 1 und 2 sind noch nicht alle Mechanismen der Interaktion der NSAID mit kopfschmerzrelevanten pathophysiologischen Prozessen bekannt. Wir geben einen kurzen Überblick über die wichtigsten aktuellen Forschungsergebnisse zu NSAID und Kopfschmerzen, die Empfehlungen zum Gebrauch der NSAID zur Behandlung der primären Kopfschmerzerkrankungen und geben einen allgemeinen Überblick über die Wirkweisen und wichtigsten Nebenwirkungen der NSAID.

Summary

For decades NSAIDs are being used in the treatment of primary headache disorders with great benefit for patients. They belong to the basic treatment options for migraine as well as tension type headache. For the use of NSAIDs in the treatment of the remaining primary headaches there are data existing that support a differentiated use. Despite the knowledge of the effects of NSAIDs on cyclooxygenase 1 and 2 not all of the mechanisms of interaction with processes in headache relevant pathophysiology are understood. Here we present an overview of the newest research on NSAIDs relevant to headaches, the current guidelines for the treatment of primary headaches and their mentioning of NSAIDs, the known mechanisms of action as well as the most important side effects.

Schlüsselwörter

Kopfschmerz - NSAID - Therapie - Migräne

Keywords

Headache - NSAIDs therapy - migraine

Volltext

Referenzen

Literatur
1 Flower R, Gryglewski R, Herbaczynska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol 1972; 238: 104-6.
2 Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999; 339: 607-14.
3 Huntjens DRH, Spalding DJM, Danhof M, Pasqua OED. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Eur J Pain 2009; 13: 448-57.
4 Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001; 53: 1679-85.
5 Palomer A, Cabre F, Pascual J, Campos J, Trujillo MA, Entrena A. et al. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J Med Chem 2002; 45: 1402-11.
6 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
7 Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
8 Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC. et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-9.
9 Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C. et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain 2005; 128: 1442-53.
10 Beeri MS, Schmeidler J, Lesser GT, Maroukian M, West R, Leung S. et al. Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging 2012; 33 (07) 1258-64.
11 Summ O, Andreou AP, Akerman S, Goadsby PJ. A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain 2010; 11: 477-83.
12 Curra A, Coppola G, Gorini M, Porretta E, Bracaglia M, Di Lorenzo C. et al. Drug-induced changes in cortical inhibition in medication overuse headache. Cephalalgia 2011; 31: 1282-90.
13 Zimmermann K, Reeh PW, Averbeck B. S+ -flurbiprofen but not 5-HT1 agonists suppress basal and stimulated CGRP and PGE2 release from isolated rat dura mater. Pain 2003; 103: 313-20.
14 Tassorelli C, Greco R, Sandrini G, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63 (Suppl. 01) 9-22.
15 Sandrini M, Vitale G, Pini LA. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 2002; 65: 193-7.
16 Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: 541-4.
17 Ellrich J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7-14.
18 Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci 2008; 27: 917-22.
19 Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007; 148: 573-83.
20 Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH. et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191-5.
21 MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
22 Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clin Infect Dis 2000; (Suppl. 31) 05: S202-10.
23 Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS. et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-72.
24 McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44.
25 Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H. et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59: 1097-104.
26 Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol 1997; 44: 85-90.
27 Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin Jr. FE. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153: 2119-24.
28 Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005; 162: 548-58.
29 Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 303-9.
30 Lipworth L, Friis S, Blot WJ, McLaughlin JK, Mellemkjaer L, Johnsen SP. et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 2004; 11: 156-63.
31 Moreno-Ancillo A, Gil-Adrados AC, Jurado-Palomo J. Ibuprofen-induced aseptic meningoencephalitis confirmed by drug challenge. J Investig Allergol Clin Immunol 2011; 21: 484-7.
32 Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151: 1309-13.
33 Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. ScientificWorldJournal 2012; 2012: 606404.
34 Cormican LJ, Farooque S, Altmann DR, Lee TH. Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin Exp Allergy 2005; 35: 717-22.
35 Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003; 30: 2234-40.
36 Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A. et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-81.
37 Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985; 42: 582-4.
38 Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35: 1304-10.
39 Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710-5.
40 Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30: 705-9.
41 Allais G, Bussone G, De Lorenzo C, Castagnoli IGabellari, Zonca M, Mana O. et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci 2007; 28 (Suppl. 02) S225-8.
42 Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol 2010; 17: 1318-25.
43 May A, Leone M, Afra J, Linde M, Sandor PS, Evers S. et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13: 1066-77.
44 Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA 2009; 302: 2451-7.
45 Cohen AS, Matharu MJ, Burns B, Goadsby PJ. Randomized double-blind, placebo-controlled trial of high-flow inhaled oxygen in acute cluster headache. Cephalalgia 2007; 27: 1188.
46 van Vliet JA, Bahra A, Martin V, Ramadan N, Aurora SK, Mathew NT. et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60: 630-3.
47 Bahra A, Gawel MJ, Hardebo JE, Millson D, Breen SA, Goadsby PJ. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000; 54: 1832-9.
48 Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63: 1537-42.
49 May A. Headaches with (ipsilateral) autonomic symptoms. J Neurol 2003; 250: 1273-8.
50 Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63: 1637-77.
51 Mir P, Alberca R, Navarro A, Montes E, Martinez E, Franco E. et al. Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone. Neurol Sci 2003; 24: 318-21.
52 Antonaci F, Costa A, Candeloro E, Sjaastad O, Nappi G. Single high-dose steroid treatment in episodic cluster headache. Cephalalgia 2005; 25: 290-5.
53 Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl. 01) 9-160.
54 Martins IP, Parreira E, Costa I. Extratrigeminal ice-pick status. Headache 1995; 35: 107-10.
55 Ammache Z, Graber M, Davis P. Idiopathic stabbing headache associated with monocular visual loss. Arch Neurol 2000; 57: 745-6.
56 Raskin NH. The cough headache syndrome: treatment. Neurology 1995; 45: 1784.
57 Mathew NT. Indomethacin responsive headache syndromes. Headache 1981; 21: 147-50.
58 Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39: 437-8.
59 Dodick DW. Indomethacin-responsive headache syndromes. Curr Pain Headache Rep 2004; 08: 19-26.
60 Diamond S. Prolonged benign exertional headache: its clinical characteristics and response to indomethacin. Headache 1982; 22: 96-8.
61 Frese A, Rahmann A, Gregor N, Biehl K, Husstedt IW, Evers S. Headache associated with sexual activity: prognosis and treatment options. Cephalalgia 2007; 27: 1265-70.
62 Frese A, Gantenbein A, Marziniak M, Husstedt IW, Goadsby PJ, Evers S. Triptans in orgasmic headache. Cephalalgia 2006; 26: 1458-61.
63 Prakash S, Dabhi AS. Relapsing remitting hypnic headache responsive to indomethacin in an adolescent: a case report. J Headache Pain 2008; 09: 393-5.
64 Pinessi L, Rainero I, Cicolin A, Zibetti M, Gentile S, Mutani R. Hypnic headache syndrome: association of the attacks with REM sleep. Cephalalgia 2003; 23: 150-4.
65 Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia 2007; 27: 1082-4.
66 Martins IP, Gouveia RG. Hypnic headache and travel across time zones: a case report. Cephalalgia 2001; 21: 928-31.
67 Ghiotto N, Sances G, Di Lorenzo G, Trucco M, Loi M, Sandrini G. et al. Report of eight new cases of hypnic headache and mini-review of the literature. Funct Neurol 2002; 17: 211-9.
68 Evers S, Rahmann A, Schwaag S, Ludemann P, Husstedt IW. Hypnic headache – the first German cases including polysomnography. Cephalalgia 2003; 23: 20-3.
69 Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache 2006; 46: 1205-6.
70 Seidel S, Zeitlhofer J, Wöber C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia 2008; 28: 1086-90.
71 Peters N, Lorenzl S, Fischereder J, Botzel K, Straube A. Hypnic headache: a case presentation including polysomnography. Cephalalgia 2006; 26: 84-6.
72 Centonze V, D’Amico D, Usai S, Causarano V, Bassi A, Bussone G. First Italian case of hypnic headache, with literature review and discussion of nosology. Cephalalgia 2001; 21: 71-4.
73 Lisotto C, Rossi P, Tassorelli C, Ferrante E, Nappi G. Focus on therapy of hypnic headache. J Headache Pain 2010; 11: 349-54.
74 Lu SR, Liao YC, Fuh JL, Lirng JF, Wang SJ. Nimodipine for treatment of primary thunderclap headache. Neurology 2004; 62: 1414-6.
75 Porta-Etessam J, Cuadrado M, Rodriguez-Gomez O, Garcia-Ptacek S, Valencia C. Are Cox-2 drugs the second line option in indomethacin responsive headaches?. J Headache Pain 2010; 11: 405-7.
76 Rossi P, Tassorelli C, Allena M, Ferrante E, Lisotto C, Nappi G. Focus on therapy: hemicrania continua and new daily persistent headache. J Headache Pain 2010; 11: 259-65.